



March 10, 2021

VIA E-MAIL & UPS EXPRESS MAIL

Robert A. Eslinger, DO, HMD
Reno Integrative Medical Center
6110 Plumas St.
Suite B
Reno, NV 89519

Dear Dr. Eslinger:

The Office of Compliance and Biologics Quality in the Center for Biologics Evaluation and Research (CBER) of the United States Food and Drug Administration (FDA) has reviewed your website available at www.renointegrativemedicalcenter.com, as well as other information available to FDA.

Cancer immunotherapy product

On your website, you market an immunotherapy product to treat or prevent cancer. For example, in a video on Reno Integrative Medical Center's website, entitled "Dr. Bob on: Dendritic Cell Vaccine," www.renointegrativemedicalcenter.com/dendritic-cell-vaccine/, you state:

- "At Reno Integrative Medical Center, we use a simplified version of a dendritic cell vaccine. Well, what does that mean? It means we concentrate the specific type of white blood cell, called a T-cell or a T-lymphocyte...take it out of the body, concentrate it, ...and technically educate or re-educate those T-cells in such a way that enables them to start killing cancer cells. And then the next day, we re-insert or inject it back into that patient's muscle. And all it is, is their own cells going back in so there is no complications or bad reactions that we have ever seen in years of doing this vaccine. The way that this works, is it's a very specific way to strengthen the person's own immune system to be able to start finding and killing abnormal or cancer cells, because that's what their normal job is. However, this technique of creating this vaccine enhances their ability to perform that function."

Similarly, your website further describes your cancer immunotherapy product:

- "Dendritic Cell Vaccine therapy offers a new promising immunotherapeutic approach for treatment of advanced cancer, as well as for secondary prevention of cancer."

- “Dendritic Cell Vaccine Therapy This therapy stimulates T-cells to generate anti-cancer cytokines that seek out abnormal cells in the body.”
- “This type of Dendritic cell vaccine is used to treat a variety of malignancies such as: pancreatic cancer, liver cancer, leukemia, multiple myeloma, colon cancer and ovarian cancer, to name a few.”
- “A sample of the patients’ blood is drawn. The white blood cells (including the T-cells) are concentrated and harvested from the blood. Once subjected to a proprietary heating process, that activates them to produce compounds called ‘heat shock proteins’, they are injected back into the patient. This activates the T-cells in such a way that they become aggressive cancer killers.”

The above-referenced product appears to be a human cell, tissue, or cellular or tissue-based product (HCT/P) as defined in 21 CFR 1271.3(d) that would be subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the Public Health Service Act (PHS Act) [42 U.S.C. 264].

HCT/Ps that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and/or biological products under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and/or the PHS Act, and are subject to additional regulation, including appropriate premarket review.

Based on a review of your website, it appears that Reno Integrative Medical Center does not qualify for any exception in 21 CFR 1271.15, and that your cancer immunotherapy product is intended for nonhomologous uses. Additionally, the product appears not to meet all the other criteria in 21 CFR 1271.10(a) and, accordingly, would be regulated as a drug as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].

In order to lawfully market a drug that is also a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].

As noted above, your cancer immunotherapy product is intended to treat or prevent a serious or life-threatening disease or condition. Such an unapproved use raises potential significant safety concerns. We direct your attention to FDA’s comprehensive regenerative medicine policy framework for HCT/Ps, which is intended to spur innovation and efficient access to safe and effective regenerative medicine products. The policy framework is outlined in a suite of four guidance documents available on FDA’s website

at <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/framework-regulation-regenerative-medicine-products>.

Manufacturers and health care professionals who have any uncertainty regarding the regulatory status of their products are encouraged to contact FDA to obtain a recommendation or decision regarding the classification of an HCT/P. For more information in this regard, or to obtain further information about IND requirements for biological products, please see pages 24 and 25 of the guidance entitled, “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use” at the link to FDA’s webpage provided above.

Exosome product

We note that, on your website, you also market an exosome product to treat diseases or conditions such as cancer and neurodegenerative diseases. For example, you were quoted on the website, www.renointegrativemedicalcenter.com/beyond-stem-cells-with-exosomes/, stating:

- “The reason I am so excited to be offering this new cutting-edge therapy is the broad range of diseases and conditions that it can treat”

Furthermore, your website states:

- “Exosomes can be administered by IV or injected in to joints.”
- “...this therapy can be given to cancer patients, whereas stem cells cannot.”
- “[Exosomes] can offer benefit in treating the neurodegenerative diseases.”

Please be advised that as a general matter, exosome products intended to treat diseases or conditions in humans are regulated as drugs and biological products under section 351 of the PHS Act and the FD&C Act and are subject to premarket review and approval requirements. For more information, please see FDA’s Public Safety Notification on Exosome Products, at <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products>.

This letter is not intended to be an all-inclusive review.¹ You and your firm are

¹ Although not the focus of this letter, you have marketed human umbilical cord and amniotic tissue derived cellular products on your website. These products appear to be HCT/Ps as defined in 21 CFR 1271.3(d) subject to regulation under 21 CFR Part 1271, issued under authority of section 361 of the PHS Act [42 U.S.C. 264]. Please be advised that HCT/Ps that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are regulated as drugs, devices, and/or biological products under the FD&C Act and/or the PHS Act, and are subject to

responsible for ensuring that all your products fully comply with the FD&C Act, the PHS Act, and all applicable regulations. We request a written response within 30 days of your receipt of this letter. Your response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, Bldg. 71, Silver Spring, MD 20993 and/or to CBERDCMRecommendations@fda.hhs.gov. If you have any questions regarding this letter, please contact the Division of Case Management, CBER at (240) 402-9155. Please be advised that only written communications are considered official.

Sincerely,

Mary A. Malarkey
Director
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research

additional regulation, including appropriate premarket review requirements.